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632Objective: Progression of functional tricuspid regurgitation is not uncommon after mitral valve surgery and is
associated with poor outcomes. We tested the hypothesis that concomitant tricuspid valve annuloplasty in pa-
tients with tricuspid annulus dilatation (40 mm) prevents tricuspid regurgitation progression after mitral valve
surgery.
Methods: We enrolled 44 patients undergoing mitral valve surgery (both repair or replacement) showing less
than moderate (þ2) tricuspid regurgitation and dilated tricuspid annulus (40 mm) at preoperative echocardi-
ography. They were randomized to receive (n ¼ 22) or not receive (n ¼ 22) concomitant tricuspid annuloplasty
(Cosgrove–Edwards annuloplasty ring; Edwards Lifesciences, Irvine, Calif) at the time of mitral valve surgery.
Clinical and echocardiographic follow-up was 100% completed at 12 months after surgery.
Results: Preoperative clinical and echocardiographic characteristics were comparable in the 2 groups. Operative
mortality was 4.4% (1 death in each group). At 12 months follow-up, tricuspid regurgitation was absent in 71%
(n¼ 15) versus 19% (n¼ 4) of patients in the treatment and control groups, respectively (P¼ .001). Moderate to
severe tricuspid regurgitation (þ3) was present in 0% versus 28% (n¼ 6) of patients in the treatment and con-
trol groups, respectively (P ¼ .02). Pulmonary artery systolic pressure significantly decreased from baseline in
all cases (P<.001) and was comparable in the 2 groups (41  8 mm Hg vs 40  5 mm Hg; P ¼ .4). Right ven-
tricular reverse remodeling was marked in the treatment group (right ventricular long axis: 71 7 mm vs 65 8
mm; P ¼ .01; short axis: 33  4 mm vs 27  5 mm; P ¼ .001) but only minimal in the control group (right
ventricular long axis: 72  6 mm vs 70  7 mm; P ¼ .08; short axis: 34  5 mm vs 33  5 mm; P ¼ .1).
The 6-minute walk test improved from baseline in both groups (P<.001), but this improvement was greater
in the treatment group (þ115  23 m from baseline vsþ75  35 m; P ¼ .008).
Conclusions: Prophylactic tricuspid valve annuloplasty in patients with dilated tricuspid annulus undergoing
mitral valve surgery was associated with a reduced rate of tricuspid regurgitation progression, improved right
ventricular remodeling, and better functional outcomes. (J Thorac Cardiovasc Surg 2012;143:632-8)Functional or secondary tricuspid regurgitation (TR) refers
to TR typically seen in association with left-sided valve
dysfunction and occurring in the absence of intrinsic pathol-
ogy of the tricuspid valve (TV) leaflets or chordae. Histor-
ically, functional TR was managed conservatively because
it was sometimes observed to decrease or even disappear af-
ter surgical correction of mitral valve disease.1,2 However,
moderate to severe late functional TR has been reported
in up to one third of patients after isolated mitral surgery
for rheumatic,3 functional,4 ischemic,4 and degenerative
mitral valve disease.5 Severe TR late after cardiac surgerye Cardiac Surgery Department, University of Rome Sapienza, Azienda Ospe-
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The Journal of Thoracic and Cardiovascular Surgis associated with substantial morbidity and mortality,6,7
and there is some evidence to suggest that even moderate
degrees of functional TR may have an adverse impact on
survival and functional outcome.8 Concomitant TVannulo-
plasty at the time of mitral surgery is a safe and effective
method of preventing progression of functional TR,5-9 and
consensus guidelines therefore recommend tricuspid
repair for moderate TR.10,11 Because TR is highly
dynamic,12 tricuspid annular dilatation of 40 mm or greater
has also been proposed as an indication for prophylactic tri-
cuspid annuloplasty10 because it seems to be a risk factor
for the development of late functional TR.5 Unlike TR
grade, tricuspid annular dilatation is a relatively objective
measurement that can be assessed independently of the pa-
tient’s hemodynamic status.13
Although significant reductions in grade and progres-
sion of functional TR after cardiac surgery have been ob-
served with TV annuloplasty,5 the benefit of prophylactic
TV annuloplasty remains controversial. We therefore de-
signed this study to test the hypothesis that concomitant
TV annuloplasty in patients with tricuspid annulus dilata-
tion (40 mm) prevents TR progression after mitral valveery c March 2012
Abbreviations and Acronyms
NYHA ¼ New York Heart Association
RV ¼ right ventricular
TR ¼ tricuspid regurgitation
TV ¼ tricuspid valve
Benedetto et al Acquired Cardiovascular Diseasesurgery and to evaluate whether this is associated with im-
proved right ventricular (RV) remodeling or a functional
benefit.A
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DPATIENTS AND METHODS
Among consecutive patients undergoing mitral valve surgery (both re-
pair or replacement) combined or not combined with coronary artery by-
pass grafting between May 2008 and September 2009, 56 patients were
enrolled who presented the following criteria at preoperative echocardio-
graphic examination: (1) less than moderate (þ2) functional TR and (2)
dilated tricuspid annulus (40 mm). Exclusion criteria were urgent opera-
tion, presence of pacemaker leads through the tricuspid annulus, acute en-
docarditis, and previous surgical procedure on TV.
A total of 44 patients were randomized to receive (n ¼ 22 treatment
group) or not receive (n¼ 22, control group) concomitant TVannuloplasty
at the time of mitral valve surgery. The local ethics committee approved
this study, and each patient signed an informed consent form.
Clinical Assessment
At baseline and the 12-month follow-up, functional NewYork Heart As-
sociation (NYHA) class was assessed and 6-minute walk test was per-
formed in every patient by a physician who was blinded to the treatment
assigned. The 6-minutewalk test was performed on a level surface. Patients
were instructed to cover the greatest distance possible during the allotted
time, at a self-determined walking speed, pausing to rest when needed.
The distance covered was measured by a body-borne pedometer, as previ-
ously reported by Roul and colleagues.14
Medications assumed at follow-up were reported, including diuretics (fu-
rosemide and hydrochlorothiazide), calcium-channel blockers, b-blockers,
and angiotensin-converting enzyme inhibitors/angiotensin receptorblockers.
Echocardiography
A transthoracic echocardiogramwas performedwithin 7 days before the
operation and at 1-year follow-up. Images were obtained using a Hewlett-
Packard (Palo Alto, Calif) Sonos 2500 or 5500 imaging system equipped
with a 2.5-MHz transducer in the parasternal and apical views (standard
long-axis, 2-chamber, and 4-chamber images). The left atrial diameter
and left ventricular dimensions (end-systolic and end-diastolic diameters)
were determined from parasternal M-mode acquisitions. Color flow was
applied in the apical views to evaluate TR. The maximal TR jet area visu-
alized using color Doppler flow mapping was used for TR quantification,
with a TR jet-to-right atrial area ratio of less than 10% ¼ grade 1þ, 10%
to 20% ¼ 2þ, 20% to 40% ¼ 3þ, and greater than 40% ¼ 4þ.15 Systolic
reversal of hepatic venous flow was also used as a criterion for 4þ TR.
The peak systolic TR jet velocity measured by CW.
Doppler was used to calculate the TR peak pressure gradient using the
simplified Bernoulli equation (pressure gradient ¼ 4 [velocity]2) to esti-
mate the peak systolic pulmonary artery pressure. Assessment of the RV
was made as previously described.16 From the apical 4-chamber view,
the ultrasound beam was oriented to obtain the maximum dimensions of
the RV chamber. The middle third of the RV was identified as lying below
the inflow tract region. A measurement of the maximum dimension of thisThe Journal of Thoracic and Caportion of the chamber was recorded as the RV short axis. The major axis of
the RV was also measured from this view and defined as the distance be-
tween the RVapex to the mid-point of the TVannulus. The TVannular di-
mension was measured as the point of attachment of the septal and
posterior leaflets to the atrioventricular junction in the transthoracic apical
4-chamber view in late diastole at the time of maximal tricuspid opening.
Because the results of annuloplasty with an annuloplasty ring are generally
apparent, the physician who performed the echocardiographic follow-up
was not blinded to treatment.
Surgical Procedure
All patients were operated via a full median sternotomy under cardio-
pulmonary bypass at normothermia. Double venous cannulation was
used. Myocardial protection consisted of antegrade cold-blood cardiople-
gia. Patients with an indication for revascularization underwent coronary
artery bypass grafting first. Patients with a history of atrial fibrillation
and a left atrium diameter less than 60 cm underwent left atrial lesion set
of the Maze procedure by means of bipolar radiofrequency.
The mitral valve was approached through a standard left atriotomy. In
the case of degenerative disease, mitral valve reconstruction was conducted
by using standard Carpentier techniques or artificial chordae implantation.
Mitral annuloplasty was routinely performed using a flexible ring
(Cosgrove-Edwards Annuloplasty System; Edwards Lifesciences, Irvine,
Calif), and ring size was determined by means of standard measurement
of the surface of the anterior leaflet. In case of ischemic functional mitral
regurgitation, a remodeling annuloplasty using the Carpentier-McCarthy-
Adams IMR ETlogix annuloplasty ring (Edwards Lifesciences) was per-
formed. Mitral valve replacement was routinely performed in rheumatic
mitral disease.
In the treatment group, the right atrium was opened horizontally in all
patients after left atrium closure. A remodeling tricuspid annuloplasty
with the flexible Cosgrove-Edwards Annuloplasty System (Edwards Life-
sciences) was performed. The appropriate size was selected on the basis of
the length of the attachment of the tricuspid septal leaflet. Transesophageal
echocardiography was used to confirm the competence of the repair.
Statistical Analysis
The primary end point was the occurrence of moderate to severe (3þ)
functional TR at 1 year follow-up. A sample size of approximately 19 pa-
tients per arm was estimated on the basis of a prevalence of 40% for the
primary outcome, as previously shown,17 a 35% clinically meaningful dif-
ference between groups, and 80% power at a 0.05 significance level to re-
ject the null hypothesis of equal rate for treatment versus control group.
A computer-generated random list (GraphPad Software, Inc, La Jolla, Ca-
lif) was used to allocate patients in each group on the day of surgery.
For categoric data, the statistical evaluation of the results was carried out
by means of the Fisher exact test to calculate an exact P value for a 2 3 2
frequency table with a small number of expected frequencies, for which the
chi-square test was not appropriate.
For continuous data, 2 (between 2 treatment groups)3 2 (repeated mea-
sures with 2 levels: basal and second evaluation) analysis of variance was
used to (1) compare basal values between the 2 groups, (2) evaluate longi-
tudinal changes within each group, and (3) compare the effects of treat-
ments (treatment vs control) on echocardiographic parameters and
clinical outcomes. Data were reported as mean  standard deviation. Sta-
tistical analyses were performed using the Statistical Package for the Social
Sciences, version 11 (SPSS Inc, Chicago, Ill).
RESULTS
Preoperative Characteristic
Preoperative patient demographics are listed in Table 1.
There was no statistically significant difference between
the 2 groups with regard to age, sex, history of atrialrdiovascular Surgery c Volume 143, Number 3 633
TABLE 1. Baseline clinical characteristics
Treatment
group
(n ¼ 22)
Control
group
(n ¼ 22) P
Female, n y (%) 9 (40%) 11 (50%) .7
Mean age (y) 64  15 68  19 .44
Prior cardiac surgery, n (%) 1 (4%) 1 (4%) .4
Prior myocardial infarction, n (%) 3 (14%) 6 (27%) .5
Diabetes, n (%) 7 (32%) 4 (18%) .4
Renal failure, n (%) 1 (4%) 0 (0%) .9
Hypertension, n (%) 15 (68%) 11 (50%) .3
PVD, n (%) 3 (14%) 4 (18%) 1
History of atrial fibrillation, n (%) 9 (40%) 12 (54%) .5
Cause of MV disease, n (%) .6
Degenerative 8 (36%) 8 (36%)
Rheumatic 8 (36%) 6 (27%)
Functional 5 (22%) 7 (32%)
Prosthesis dysfunction 0 (0%) 1 (4%)
Failure of MV repair 1 (4%) 0 (0%)
MV lesion, n (%) .9
Regurgitation 16 (72%) 15 (68%)
Stenosis 2 (9%) 3 (14%)
Mixed 4 (18%) 4 (18%)
NYHA functional class, n (%) .5
I–II 5 (22%) 8 (36%)
III–IV 17 (77%) 14 (63%)
6-min walk test (m) 354  57 361  49 .6
PVD, Peripheral vascular disease; MV, mitral valve; NYHA, New York Heart
Association.
TABLE 3. Twelve-month follow-up echocardiographic characteristics
Treatment
group (n ¼ 21)
Control
group (n ¼ 21) P
Left atrial diameter (mm) 41  4 40  6 .5
LV end-diastolic diameter (mm) 56  7 57  8 .6
LV end-systolic diameter (mm) 34  10 35  5 .6
LV ejection fraction (%) 50  8 51  6 .7
RV long axis (mm) 65  8 70  7 .03
RV short axis (mm) 27  5 33  8 .005
TV annulus (mm) 36  4 41  3 .01
TR grade, n (%) .007
0þ 15 (72%) 4 (19%)
1þ 3 (14%) 5 (24%)
2þ 3 (14%) 6 (29%)
3þ 0 (0%) 5 (24%)
4þ 0 (0%) 1 (4%)
Pulmonary artery systolic
pressure (mm Hg)
41  8 40  5 .6
LV, Left ventricular; RV, right ventricular; TV, tricuspid valve; TR, tricuspid
regurgitation.
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tional class, and 6-minute walk test. The underlying cause
and valvular lesion of mitral valve were similar in both
groups, with the predominant lesion being degenerative mi-
tral regurgitation. Preoperative echocardiographic charac-
teristics are presented in Table 2. Left ventricular
dimensions and function were comparable between the 2
cohorts. TR grade was similar between both cohorts, as
were RV dimensions.TABLE 2. Baseline echocardiographic characteristics
Treatment
group (n ¼ 22)
Control
group (n ¼ 22) P
Left atrial diameter (mm) 48  9 47  8 .7
LV end-diastolic diameter (mm) 60  5 61  7 .5
LV end-systolic diameter (mm) 39  9 37  7 .4
LV ejection fraction (%) 51  8 55  7 .09
RV long axis (mm) 71  7 72  6 .6
RV short axis (mm) 33  4 34  5 .47
TV annulus (mm) 43  3 44  3 .28
TR grade, n (%) .6
0þ 9 (41%) 12 (54%)
1þ 7 (32%) 5 (23%)
2þ 6 (27%) 5 (23%)
Pulmonary artery systolic
pressure (mm Hg)
48  4 49  4 .47
LV, Left ventricular; RV, right ventricular; TV, tricuspid valve; TR, tricuspid
regurgitation.
634 The Journal of Thoracic and Cardiovascular SurgOperative Outcomes
The rate of mitral valve repair was similar in both treat-
ment (54%, n ¼ 12) and control (63%, n ¼ 14) groups
(P ¼ .75). Coronary artery bypass grafting was performed
in both treatment (22%, n ¼ 5) and control (32%, n ¼ 7)
groups (P ¼ .73). Left atrial lesion set of the Maze proce-
dure was performed in both treatment (27%, n ¼ 6) and
control (41%, n ¼ 9) groups (P ¼ .52). Cardiopulmonary
bypass time and clamp time were slightly increased in the
treatment group: 139 37 versus 120 66minutes, respec-
tively (P ¼ .07). The tricuspid median ring size used in the
treatment group was 32 mm. No correlation was found be-
tween ring size and TR grade at follow-up (nonparametric
P¼ .2). The 30-day mortality was the same in the treatment
(4.4%, n¼ 1) and control (4.4%, n¼ 1) groups, with death
attributed to low cardiac output syndrome and pneumonia,
respectively, in patients undergoing operation for functional
mitral regurgitation. The mean length was the same in the
treatment (7 days) and control (7 days) groups (P ¼ 1).
Follow-up
All operative survivors completed the 12-month follow-
up. Echocardiographic follow-up is presented in Table 3.
All patients who had mitral valve repair showed no late re-
current mitral regurgitation of greater than grade 1þ. No mi-
tral valve prosthesis dysfunction was detected. As expected,
after surgical intervention on the mitral valve, a reduction in
left atrial and left ventricular dimensions was observed in
both groups, as well as in pulmonary artery systolic pres-
sure, which significantly decreased from baseline in both
groups (P<.001).
TR was more often absent in the treatment group (71%,
n ¼ 15) than in the control group (19%, n ¼ 4) (P ¼ .001).
New onset of moderate to severe TR (þ3) was completely
absent in the treatment group (0%, n¼ 0) but was observedery c March 2012
FIGURE 1. Mean TR grade at follow-up according to the cause of mitral
valve disease. TV, Tricuspid valve. FIGURE 2. Percentage of improvement in echocardiographic measure-
ments of right ventricular (RV) remodeling. TV, Tricuspid valve; PASP, pul-
monary artery systolic pressure; LA, left atrium.
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grade of TR in treatment and control groups according to
mitral valve cause is shown in Figure 1.
RV reverse remodeling was substantial in the treatment
group (RV long axis: 71  7 mm vs 65  8 mm; P ¼ .01;
RV short axis: 33  4 mm vs 27  5 mm; P ¼ .001) but
only marginal in the control group (RV long axis: 72  6
mm vs 70  7 mm; P ¼ .08; RV short axis: 34  5 mm
vs 33  5 mm; P ¼ .1). Figure 2 shows the percentage of
improvement in echocardiographic measurements of RV re-
modeling in the 2 groups.
A significant improvement in functional class was ob-
served in both groups, and NYHA class III and IV was pres-
ent in 0% (n ¼ 0) and 4% (n ¼ 1) of patients in the
treatment and control groups, respectively (P ¼ 1).
Six-minute walk test increased in both groups (P< .001
from baseline) but was greater in the treatment group
(472  49 m vs 435  51 m; P ¼ .02; D ¼þ115  23 m
vsþ75  35 m; P ¼ .008).
Medications assumed at follow-up were similar in the
treatment and control groups: furosemide 52% (n¼ 11) ver-
sus 61% (n ¼ 13) (P ¼ .78); hydrochlorothiazide 23%
(n¼ 5) versus 42% (n¼ 9), P¼ .32; Caþþ-channel blockers
28% (n¼ 6) versus 33% (n¼ 7), P¼ .98; b-blockers 42%
(n ¼ 9) versus 57% (n ¼ 12), P ¼ .50; and angiotensin-
converting enzyme inhibitor/angiotensin receptor blockers
71% (n ¼ 15) versus 66% (n ¼ 14) (P ¼ .98).DISCUSSION
The main finding of the current study was that concomi-
tant TV annuloplasty prevents progression of TR andThe Journal of Thoracic and Capromotes RV reverse remodeling in patients who are re-
ferred to mitral valve surgery and who present tricuspid an-
nulus dilatation.
Functional TR is caused mainly by dilatation of the tri-
cuspid annulus, which results from a remodeling process
of the RV due to chronic pressure overload.12 Treatment
of the mitral valve lesion alone only decreases the afterload,
but does not correct tricuspid dilatation or directly affect
preload or RV function.5 As a consequence, complete re-
verse RV remodeling may not occur, and normalization of
pulmonary artery pressures alone will not eliminate TR in
many patients.18
In addition, several factors influence the occurrence of
functional TR: the preload, afterload, and RV function. As
occurs for functional mitral regurgitation, these factors
can interfere with regard to the severity of TR under differ-
ent conditions, and significant TR may not be detected by
echocardiography despite considerable tricuspid annulus
dilatation. Therefore, the regurgitation severity alone as-
sessed by echocardiography is probably not sufficient to
screen for secondary TR5 and may not be reliable to identify
all patients who require TV annuloplasty.
On the basis of these observations, in recent guidelines
the tricuspid annulus dilatation is proposed as a criterion
for concomitant TV annuloplasty regardless of the degree
of TR,10,11 although the European Society of Cardiology
recommendations10 support a more aggressive approach to-
ward TV repair; meanwhile, the American College of
Cardiology/American Heart Association guidelines giverdiovascular Surgery c Volume 143, Number 3 635
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less than severe TR.11
The TV annulus diameter may be measured intraopera-
tively, from the anteroseptal commissure to the anteroposte-
rior commissure, and TVannuloplasty should be considered
when the tricuspid annulus diameter is 7 cm or more.5
However, echocardiographic measurement of the tricus-
pid annulus diameter has been proposed as an alternative
approach to the intraoperative assessment. A tricuspid an-
nulus diameter of 40 mm or more has been demonstrated
to be equivalent to 7 cm intraoperatively (A. Berrebi, per-
sonal communication, November 2006). This cutoff accu-
rately identifies patients undergoing mitral valve repair
without concomitant TVannuloplasty who have poor echo-
cardiographic outcomes, including significant TR and lack
of RV reverse remodeling at follow-up,19 and it has been
proposed to screen patients for TV repair.10
This strategy has been recommended particularly in pa-
tients with rheumatic and ischemic disease.20 Perplexity re-
mains about the usefulness of concomitant prophylactic TV
repair in degenerative mitral valve disease.21 Recent find-
ings confirmed that clinically silent, nonsevere TR in this
setting is unlikely to progress after mitral valve surgery.22
This may be partially because patients with mitral valve
leaflet prolapse are more likely to have early mitral valve re-
pair even when they are completely asymptomatic, thus
avoiding long-standing RV pressure overload, which pre-
disposes to late functional TR.
In the present study, the advantage of TV annuloplasty
was substantial in rheumatic and ischemic disease, but we
found no statistically significant trend toward a benefit in
degenerative cause. It should be underlined that patients
with degenerative mitral valve disease included in the pres-
ent study presented 2 main baseline characteristics that may
partially explain the observed advantage of prophylactic TV
annuloplasty that was not reported by others in the same
clinical setting22: a higher rate of functional NYHA class
III and IV (62.5% vs 34.6%) and preoperative history of
atrial fibrillation (50% vs 17.5%). This observation sug-
gested that in the present cohort, patients with a generative
cause were less likely to undergo early surgery, thus being
exposed to long-standing RV pressure overload. In addition,
atrial fibrillation has been demonstrated as a main risk fac-
tor for progression of functional TR after mitral valve dis-
ease.23 These considerations suggest the hypothesis that
in degenerative mitral valve disease, TV annuloplasty
should be considered regardless of the absolute grade of
TR when preoperative atrial fibrillation or congestive heart
failure symptoms are present.
Study Limitations
This study has several limitations. The small sample size
precludes meaningful conclusion on differences in major
adverse clinical outcomes. In addition, the assessment of636 The Journal of Thoracic and Cardiovascular Surgprimary end point cannot be blinded. The semiquantitative
assessment of TR grade was open to operator bias. The
grade of TR is dynamic. In such a small study, individual
differences in hemodynamic status may have influenced
the overall prevalence of TR.
The study is underpowered to detect clinically important
differences in operative mortality, and the absence of statis-
tically significant differences in mortality does not permit
us to draw any conclusion about operative risk related to
TV annuloplasty. TV annuloplasty has been associated
with a higher rate of pacemaker requirement.5 In the present
study, no patients receiving a TV annuloplasty required
a pacemaker, and it could be speculated that by using a flex-
ible band the conduction system of the heart is not jeopar-
dized because sutures are not placed in this vicinity.
CONCLUSIONS
The present study confirmed that a tricuspid annulus di-
ameter of 40 mm or greater was associated with an in-
creased risk of progression of functional TR when TV
repair was not performed. We found that prophylactic TV
annuloplasty prevents the progression of functional TR,
thus promoting RV reverse remodeling. The advantage of
concomitant tricuspid annuloplasty was substantial in rheu-
matic and functional disease. Future studies with a longer
follow-up and larger sample size are required to confirm
that prophylactic tricuspid annuloplasty prevents the pro-
gression of secondary TR at mid- and long-term follow-
ups and that this will transform into clinical benefit for
patients.
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Discussion
Dr W. Randolf Chitwood (Greenville, NC). In this study, you
prospectively randomized 44 patients undergoing mitral surgery
who had concomitant TR with a dilated annulus to receive or
not receive a concomitant band annuloplasty. By preoperative
echocardiography, each cohort had less than 2+ TR but a dilated
annulus to more than 40 mm by echocardiography. At 12 months
after surgery, the annuloplasty cohort had no TR and only 19% in
the control group had no TR. The absence of TR was reflected in,
as you said, reversed remodeling and improvement in patient func-
tionality. On the basis of your data, you are suggesting that we per-
form prophylactic ringing of the TV.
Many share your view that correction of mitral insufficiency
does not correct functional TR automatically. Treatment of this mi-
tral lesion alone decreases the afterload but does not correctThe Journal of Thoracic and Catricuspid annular dilatation, preload, or RV function. The TV
may have significant pathologic changes even when associated
with mild regurgitation. We know that. Moreover, differential
loading conditions often make the preoperative echocardiographic
assessment inaccurate.
The seminal article by Dreyfus and colleagues5 in 2005 recom-
mended that the decision to perform a tricuspid annuloplasty
should be based on annular diameter rather than the level of regur-
gitation, and they considered that an annular diameter of more than
70 mm (now, this was measured directly in the operating room, not
on echocardiography, and that was more than twice the diameter of
the normal valve) was an indication for a concomitant ring or re-
pair. Your study has shown that RV reverse remodeling is good
and functionality is great. What was the size of the valve annulus
when you were in the operating room? Professor Mohr subscribes
to the same thing in Leipzig if it is more than 65 mm.
In contrast, at the Mitral Valve Conclave in New York City, Ra-
kesh Suri from the Mayo Clinic reported a large series of patients
with different levels of tricuspid insufficiency. They showed that
grades 1 and 2 regurgitation progressed only slightly over time
and that atrial fibrillation was a risk factor. So lower levels of
TR did not affect long-term survival, and they did not put a ring
in. That is in contradistinction to what you are saying.
Many surgeons still do not agree with a ‘‘prophylactic tricuspid
annuloplasty.’’ Moreover, there is even disagreement between our
guidelines in Europe and the United States. In Europe, a class IIa
indication exists formoderate TRwith a dilated annulus in a patient
undergoing a mitral valve operation, but in the United States, our
guidelines state that a tricuspid annuloplasty ‘‘may be considered’’
a class IIb indication in the presence of annular dilatation and pul-
monary hypertension. Therefore, there is a significant conundrum
between surgeons and cardiologists on what to do.
I have 3 questions for you. Considering that the tricuspid
annular size can vary with loading conditions and that echocardi-
ography measurements can be inaccurate, do you measure the an-
nulus intraoperatively? I think you said you just use the anterior
leaflet to size the ring or band you were using. Do you put any cre-
dence in the intraoperative measurement?
Dr Benedetto. We decided to measure the tricuspid annulus
with preoperative echocardiography because we think that intrao-
perative measurement is not reliable or easily reproducible. We
found an agreement between the judgment of tricuspid dilatation
assessed by preoperative echocardiography and intraoperative
examination.
Dr Chitwood. Did you perform transesophageal echocardiog-
raphy in the operating room or is this all transthoracic?
Dr Benedetto. In the operating room we did not perform trans-
esophageal echocardiography to measure the annulus but only to
assess the result of TV repair.
Dr Chitwood. The second question is, Jim Gammie recently
suggested—and this will be published in the Annals of Thoracic
Surgery, it is in press—using an undersized ring to repair the
TV. They used no ring larger than 28 mm. What is your optimal
size and does it matter as long as it is a smaller annulus? What
do you think the optimal size is?
Dr Benedetto. The median ring size in our series was 32 mm.
We select the ring size on the basis of the septal leaflet attachment,
and we did not undersize this measure.rdiovascular Surgery c Volume 143, Number 3 637
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C
DDr Chitwood. Many patients who do have moderate to severe
tricuspid insufficiency, and have a repair and the ventricle changes,
develop recurrent tricuspid disease. What do you do when you
have that dilated ventricle, pulmonary hypertension, and more
than moderate regurgitation? Do you just put a ring in or do you
augment? What do you do?
Dr Benedetto.We are aware that functional tricuspid pathology
is similar to functional mitral regurgitation and that the result of
tricuspid repair is strongly related to the preoperative RV condi-
tions. In patients with a highly remodeled right ventricle, the
risk of a failure is high. However, we do not adopt an alternative
surgical strategy in these cases.
Dr Patrick McCarthy (Chicago, Ill). By way of disclosure, I
am the inventor of the MC3 ring (Edwards Lifesciences, Irvine,
Calif). I was interested in the atrial fibrillation at 1 year. Do you
have any data on how common that was? Was that, for instance,
more common in the control group and did it correlate with the
6-minute walk test? Excellent article, and it was good to see a pro-
spective randomized surgical trial.
Dr Benedetto. For the small sample size, subgroup analysis was
not possible, but we have the data for atrial fibrillation. Nine pa-
tients in the annuloplasty group had a history of atrial fibrillation,
and 6 of them underwent aMaze procedure. Because 3 of them had
a left atrium greater than 60 mm, we decided not to perform this
procedure in these patients. Therefore, at 1-year follow-up, 5 pa-
tients treated had sinus rhythm and only 1 patient had atrial fibril-
lation. In our annuloplasty group, of 12 patients with a preoperative638 The Journal of Thoracic and Cardiovascular Surghistory of atrial fibrillation, 9 were treated because the others had
a left atrium greater than 60 mm. Only 1 patient had recurrence of
atrial fibrillation. Overall, we had persistent sinus rhythm in ap-
proximately 80% of patients treated for atrial fibrillation.
Dr Norberto De Vega (Malaga, Spain). I rise to congratulate
Dr Benedetto and colleagues for the elegant presentation. Forty
years ago, a Canadian surgeon, Pierre Groudin, published a semi-
nal article in the Journal, ‘‘The Tricuspid Valve: A Surgical Chal-
lenge.’’ Since then, that was 40 years, for too many years we
surgeons have been trying to find the best technique to address
the problem instead of trying to find the best indication. Unfortu-
nately, many times we have followed the indications of the cardi-
ologists, who have been wrong. Nowadays, I believe that in most
mitral surgical cases, the tricuspid annulus should be fixed or re-
duced. It can be done without any added risk and can prolong
the well-being of many patients for many years.
Have you ever tried any other technique apart from the ring? I
know that my Indian and Chinese friends who probably are here
would agree that $2000 for this prophylactic surgery may be too
much for many patients.
Dr Benedetto. We decided to perform tricuspid annuloplasty
with a ring because recent evidence suggests that ring annuloplasty
is associated with better results than suture annuloplasty. However,
the policy in our department is to routinely performDeVega suture
annuloplasty. In the present study, we used ring annuloplasty to
avoid any criticism, but outside of the present study, we have op-
timal results with the De Vega technique.ery c March 2012
